CLOS
COGT icon

Compagnie Lombard Odier SCmA’s Cogent Biosciences COGT Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$665 – 533
2019
Q1 		$1K Buy
+50
New +$855 ﹤0.01% 562

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Compagnie Lombard Odier SCmA's COGT Position: Q2 2019 in Review

Compagnie Lombard Odier SCmA sold out of Cogent Biosciences (COGT) in Q2 2019, closing a stake of 50 shares — an estimated $665 sold.

Compagnie Lombard Odier SCmA first reported a position in COGT in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 39 funds tracked by Wall St. Rank hold COGT as of Q2 2019.

  • Compagnie Lombard Odier SCmA reported no remaining Cogent Biosciences position as of Q2 2019 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 50 Cogent Biosciences shares in Q2 2019, an estimated $665.
  • Compagnie Lombard Odier SCmA first reported a position in Cogent Biosciences in Q1 2019 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Cogent Biosciences position peaked at $1K in Q1 2019.
  • 39 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2019.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2019, filed 14 Aug 2019.